Vericel Crescita futura
Criteri Future verificati 4/6
Si prevede che Vericel aumenterà gli utili e i ricavi rispettivamente del 32.4% e 14.9% all'anno, mentre si prevede che l'EPS crescerà del 30.9% all'anno.
Informazioni chiave
32.4%
Tasso di crescita degli utili
30.92%
Tasso di crescita dell'EPS
| Biotechs crescita degli utili | 27.5% |
| Tasso di crescita dei ricavi | 14.9% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Good |
| Ultimo aggiornamento | 03 Aug 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento narrativa • Jul 31
VCEL: Raised Guidance And Buyback Will Support Stronger Forward Repricing
Analysts have raised their fair value estimate for Vericel stock from $42.00 to $55.00, citing recent price target increases that follow reported MACI performance in Q2, as well as guidance they consider achievable for the second half of the year. Analyst Commentary Recent Street research on Vericel has focused on how current expectations for MACI and the broader MedTech backdrop feed into risk and reward for the stock.
Aggiornamento narrativa • Jul 17
VCEL: Raised Outlook And New Headquarters Will Support Stronger Future Position
Vericel's implied fair value estimate has moved from about $53.88 to $57.14 as analysts adjust their price targets, citing updated expectations around revenue growth, profit margins and sector volatility. What’s in the News for Vericel Vericel approved an amendment to the company’s bylaws to reflect the relocation of its principal executive offices to a new global headquarters at 25 Blue Sky Drive, Burlington, Massachusetts 01803.
Aggiornamento narrativa • Jun 26
VCEL: Strong Q1 Execution And BARDA Contract Will Drive Future Upside
Analysts have raised their fair value estimate for Vericel to $70.00 from $64.00, citing updated assumptions on revenue growth, profit margins, and future P/E, even as some Street targets such as Truist's have recently moved lower. What’s in the News for Vericel Analysts highlighted Vericel’s recent first quarter results, where revenues were reported at 7.6% above expectations and statutory losses were reduced, according to a summary of Wall Street research (source: Zacks / TD Cowen coverage summary).Articolo di analisi • Jun 22
Vericel (VCEL) Stock Could Be 37.3% Undervalued After Earnings Beat And Fund Buying
Vericel (VCEL) has drawn fresh attention after institutional holders such as BlackRock and State Street lifted their positions, and the company reported quarterly earnings per share that came in above market expectations. See our latest analysis for Vericel. Vericel's share price has picked up momentum recently, with a 1-day share price return of 2.48%, 7-day return of 7.05%, and 90-day return of 23.57%. This comes even though the 1-year total shareholder return declined 4.57% and the 5-year...Articolo di analisi • May 09
The Vericel Corporation (NASDAQ:VCEL) First-Quarter Results Are Out And Analysts Have Published New Forecasts
As you might know, Vericel Corporation ( NASDAQ:VCEL ) just kicked off its latest quarterly results with some very...Nuova narrativa • May 02
Expanded Cell Therapy Capacity And Burn Care Franchise Will Drive Multiyear Upside Potential
Catalysts About Vericel Vericel develops and manufactures advanced cell therapies for cartilage repair and severe burn care. What are the underlying business or industry changes driving this perspective?Nuova narrativa • Apr 17
Expanded Cell Therapy Pipeline Will Face Execution Risks Yet Ultimately Support Healthier Business
Catalysts About Vericel Vericel develops and manufactures advanced cell therapies for sports medicine and burn care, including MACI for cartilage repair and Epicel and NexoBrid in burn care. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Jan 04
Vericel: Growth Plans May Have Run Out Of Gas (Rating Downgrade)
Summary Vericel (VCEL) is rated a hold due to inconsistent growth, fluctuating profitability, and limited near-term upside at current valuation. VCEL’s future hinges on scaling MACI, as Epicel and Nexobrid have stalled and face capped demand in niche markets. International expansion and MACI Arthro could drive growth, but execution risks and delayed timelines temper confidence in acceleration. Despite strong cash and no long-term debt, persistent SG&A growth and negative free cash flow highlight challenges in achieving sustainable profitability. Read the full article on Seeking AlphaArticolo di analisi • Nov 12
There's No Escaping Vericel Corporation's (NASDAQ:VCEL) Muted Revenues Despite A 29% Share Price Rise
Vericel Corporation ( NASDAQ:VCEL ) shares have had a really impressive month, gaining 29% after a shaky period...Articolo di analisi • Jun 16
Does Vericel (NASDAQ:VCEL) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Articolo di analisi • May 01
Risks To Shareholder Returns Are Elevated At These Prices For Vericel Corporation (NASDAQ:VCEL)
With a median price-to-sales (or "P/S") ratio of close to 9.6x in the Biotechs industry in the United States, you could...Seeking Alpha • Mar 06
Vericel: Scalable Growth With Strong Margins
Summary Vericel's niche in regenerative medicine is undervalued, with FDA-approved products like MACI, Epicel, and NexoBrid driving steady revenue growth and profitability. The company's strong financials include $167 million in cash, zero debt, and a 16% year-over-year revenue increase, highlighting operational efficiency. MACI's expansion into ankle cartilage repair and a robust pipeline suggest significant future earnings potential, despite current market hesitations. VCEL's strategy focuses on indication expansion and market penetration, aiming for long-term margin growth and reduced vulnerability to high-risk drug development. Read the full article on Seeking AlphaSeeking Alpha • Dec 19
Vericel Corporation: Hard To Justify Current Valuation
Summary Vericel Corporation, specializing in cellular therapies for sports medicine and severe burn care, has seen a 40% rise in its stock recently. Core products include MACI, NexoBrid, and Epicel, with Q3 revenues rising 27% year-over-year to $57.9 million, beating expectations. The company is turning the corner on profitability, but valuations look stretched at current trading levels. An analysis around Vericel follows in the paragraphs below. Read the full article on Seeking AlphaArticolo di analisi • Nov 09
Vericel Corporation (NASDAQ:VCEL) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Vericel Corporation ( NASDAQ:VCEL ) shares have had a really impressive month, gaining 32% after a shaky period...
Nuova narrativa • Sep 10
MACI And NexoBrid Drive Record Revenues And Profit Growth, Setting Stage For Robust Future Performance
Expansion of MACI and NexoBrid markets driving record revenues, indicating significant future revenue growth.Articolo di analisi • Jul 12
What Vericel Corporation's (NASDAQ:VCEL) P/S Is Not Telling You
With a median price-to-sales (or "P/S") ratio of close to 11.3x in the Biotechs industry in the United States, you...Articolo di analisi • May 11
Vericel Corporation (NASDAQ:VCEL) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Vericel Corporation ( NASDAQ:VCEL ) just released its first-quarter report and things are looking bullish. Revenues and...Articolo di analisi • Apr 26
It's Unlikely That The CEO Of Vericel Corporation (NASDAQ:VCEL) Will See A Huge Pay Rise This Year
Key Insights Vericel will host its Annual General Meeting on 1st of May Salary of US$790.0k is part of CEO Nick...Articolo di analisi • Mar 02
Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 49% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vericel fair value estimate is US$87.12 Vericel is estimated...Articolo di analisi • Feb 02
Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL) After Shares Rise 29%
Vericel Corporation ( NASDAQ:VCEL ) shareholders would be excited to see that the share price has had a great month...Articolo di analisi • May 05
Vericel Corporation's (NASDAQ:VCEL) Shareholders Might Be Looking For Exit
It's not a stretch to say that Vericel Corporation's ( NASDAQ:VCEL ) price-to-sales (or "P/S") ratio of 9.4x right now...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 455 | 73 | N/A | N/A | 7 |
| 12/31/2027 | 393 | 47 | N/A | N/A | 8 |
| 12/31/2026 | 336 | 29 | N/A | 98 | 8 |
| 6/30/2026 | 306 | 24 | 62 | 70 | N/A |
| 3/31/2026 | 292 | 21 | 47 | 62 | N/A |
| 12/31/2025 | 276 | 17 | 25 | 52 | N/A |
| 9/30/2025 | 259 | 13 | 20 | 59 | N/A |
| 6/30/2025 | 249 | 7 | -8 | 47 | N/A |
| 3/31/2025 | 239 | 3 | -7 | 58 | N/A |
| 12/31/2024 | 237 | 10 | -6 | 58 | N/A |
| 9/30/2024 | 227 | 4 | -12 | 46 | N/A |
| 6/30/2024 | 215 | 1 | -2 | 43 | N/A |
| 3/31/2024 | 208 | 0 | 2 | 35 | N/A |
| 12/31/2023 | 198 | -3 | 8 | 35 | N/A |
| 9/30/2023 | 185 | -10 | 11 | 32 | N/A |
| 6/30/2023 | 178 | -13 | 13 | 29 | N/A |
| 3/31/2023 | 169 | -17 | 9 | 22 | N/A |
| 12/31/2022 | 164 | -17 | 10 | 18 | N/A |
| 9/30/2022 | 159 | -18 | 14 | 21 | N/A |
| 6/30/2022 | 155 | -16 | 12 | 21 | N/A |
| 3/31/2022 | 158 | -11 | 14 | 22 | N/A |
| 12/31/2021 | 156 | -7 | 21 | 29 | N/A |
| 9/30/2021 | 154 | 0 | 22 | 30 | N/A |
| 6/30/2021 | 152 | 9 | 25 | 31 | N/A |
| 3/31/2021 | 132 | 4 | 19 | 23 | N/A |
| 12/31/2020 | 124 | 3 | 15 | 18 | N/A |
| 9/30/2020 | 118 | 0 | 7 | 9 | N/A |
| 6/30/2020 | 117 | 0 | 10 | 13 | N/A |
| 3/31/2020 | 123 | -12 | N/A | -3 | N/A |
| 12/31/2019 | 118 | -10 | N/A | -7 | N/A |
| 9/30/2019 | 110 | -14 | N/A | -8 | N/A |
| 6/30/2019 | 102 | -18 | N/A | -14 | N/A |
| 3/31/2019 | 95 | -3 | N/A | -1 | N/A |
| 12/31/2018 | 91 | -8 | N/A | 0 | N/A |
| 9/30/2018 | 83 | -13 | N/A | -2 | N/A |
| 6/30/2018 | 75 | -17 | N/A | -9 | N/A |
| 3/31/2018 | 73 | -15 | N/A | -10 | N/A |
| 12/31/2017 | 64 | -17 | N/A | -13 | N/A |
| 9/30/2017 | 57 | -26 | N/A | -23 | N/A |
| 6/30/2017 | 54 | -29 | N/A | -22 | N/A |
| 3/31/2017 | 50 | -31 | N/A | -22 | N/A |
| 12/31/2016 | 54 | -27 | N/A | -20 | N/A |
| 9/30/2016 | 53 | -26 | N/A | -15 | N/A |
| 6/30/2016 | 54 | -23 | N/A | -11 | N/A |
| 3/31/2016 | 54 | -22 | N/A | -11 | N/A |
| 12/31/2015 | 51 | -23 | N/A | -13 | N/A |
| 9/30/2015 | 50 | -20 | N/A | -16 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: La crescita prevista degli utili di VCEL ( 32.4% all'anno) è superiore al tasso di risparmio ( 3.7% ).
Guadagni vs Mercato: Si prevede che gli utili di VCEL ( 32.4% all'anno) cresceranno più rapidamente del mercato US ( 17.1% all'anno).
Guadagni ad alta crescita: Si prevede che gli utili di VCEL cresceranno in modo significativo nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di VCEL ( 14.9% all'anno) crescerà più rapidamente del mercato US ( 13% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di VCEL ( 14.9% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di VCEL è previsto essere elevato tra 3 anni
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/09 20:16 |
| Prezzo dell'azione a fine giornata | 2026/08/07 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Vericel Corporation è coperta da 20 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Keay Nakae | Ascendiant Capital Markets LLC |
| Michael Gorman | BTIG |
| Caitlin Cronin | Canaccord Genuity |